Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

779.28 +3.38 (+0.44%)
Official Closing Price Updated: 7:00 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eli Lilly

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Neuroblastoma Pipeline, NDA Approvals, Emerging Drugs, and Clinical Trials (2023) | Companies – Clarity Pharmaceuticals, Y mAbs Therapeutics, Nova Biopharma, Eli Lilly and Company, GE Healthcare
Via AB Newswire
Nephroblastoma Pipeline, NDA Approvals, Clinical Trials, and Emerging Drugs (2023) | Companies – Clarity Pharma, Y mAbs Therapeutics, Nova Biopharma, Eli Lilly, Illumina Radiopharma, Recombio and Other
Via AB Newswire
Ocular Melanoma Market expected to rise | Companies – Eli Lilly & Co, Spectrum Pharmaceuticals Inc, Novartis AG, Bayer, AstraZeneca plc, Merck, Amgen, Pfizer Inc, Roche, expected to drive market
Via AB Newswire
Eli Lilly and Company (NYSE: LLY) Highlighted for Surprising Price Action
Via Investor Brand Network
Eli Lilly and Company (NYSE: LLY) Climbs to New 52-Week High
Via Investor Brand Network
Eli Lilly and Company (NYSE: LLY) Climbs to New 52-Week High
Via Investor Brand Network
Eli Lilly and Company (NYSE: LLY) Climbs to New 52-Week High
Via Investor Brand Network
Hagens Berman: Settlement Worth in Excess of $500 Million Reached in Insulin Pricing Class-Action Lawsuit
From Hagens Berman
Via Business Wire
Lifestyle Drugs Market to Eyewitness Massive Growth : Eli Lilly, Pfizer, BMS, AstraZeneca
Stay up-to-date with Lifestyle Drugs Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Big pharma stocks Novartis, Eli Lilly, Merck, and Novo Nordisk are outperforming the market, driven by successful drugs and strong earnings growth. 
Via MarketBeat
Topics Economy
Eli Lilly and Company (NYSE: LLY) is a Leading Gainer in 4/21 Morning Trading
Via Investor Brand Network
Eli Lilly and Company (NYSE: LLY) Highlighted for Surprising Price Action
Via Investor Brand Network
Eli Lilly and Company (NYSE: LLY) is a Leading Gainer in Wednesday Morning Trading
Via Investor Brand Network
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
The Turnaround for Weight Watchers is Taking Shape
Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares 
Via MarketBeat
Oral Cancer Treatment Market Projected to Show Strong Growth : Bristol-Myers Squibb, Qilu Pharmaceutical, Novartis
Get Oral Cancer Treatment Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis. 
Via SBWire
Worsening Alzheimer’s Epidemic Signals A Need for More Community Memory Screening
Via AB Newswire
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027
Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons, which... 
Via FinancialNewsMedia
Topics Intellectual Property
Eli Lilly and Company (NYSE: LLY) Sets New 52-Week High in Monday Session
Via Investor Brand Network
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers 
Via MarketBeat
Can Teladoc Stock Be Resuscitated?
Virtual healthcare services company Teladoc Health Inc. (NYSE: TDOC) has had a treacherous journey rising to a high of $308 in Feb 2021 and falling to a post- 
Via MarketBeat
Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal
Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia 
Via MarketBeat
Here are 2 Top Drug Makers Leading the Way in Weight Loss Drugs
The topic of weight loss drugs has been making recent headlines. The positive phase 1 clinical trial for Viking Therapeutics Inc. (NASDAQ: VKTX) GLP-1 treatme 
Via MarketBeat
Weight Watchers Reshapes Itself with a Game-Changer Acquisition
Weight management meals and services provider WW International Inc. (NYSE: WW) spike over 25% as it closed its acquisition of telehealth weight loss platform 
Via MarketBeat
Pediatric Drugs Market Giants Spending Is Going to Boom : Pfizer, Bayer, Abbott Laboratories, Merck
NJ New Jersey, USA -- (SBWIRE) -- 04/10/2023 -- Latest Study on Industrial Growth of Pediatric Drugs Market 2022-2027. A detailed study accumulated to offer Latest insights about acute features of the... 
Via SBWire
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Oncology Translational Research Leader to Scientific Advisory Board
Via Investor Brand Network
Topics Artificial Intelligence
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP 
Via MarketBeat
Don't Be Fooled by These 3 Value Traps
Approximately one out of every ten U.S. listed stocks have a positive P/E ratio less than 10. Some are justifiably cheap; others are merely fool’s gold. 
Via MarketBeat
A Comprehensive Study Exploring Antibody Services Market : Key Players Eppendorf, Cellab, Cusabio Technology
Get Antibody Services Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis. 
Via SBWire
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
By Julian Richard, Benzinga 
Via TheNewswire.com
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.